DOCSLIB.ORG

Saskatchewan Immunization Manual Chapter 10 – Biological Products September 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Saskatchewan Immunization Manual Chapter 10 – Biological Products September 2021 Saskatchewan Immunization Manual Chapter 10 – Biological Products September 2021 TABLE OF CONTENTS 1. Refer to SIM, Chapter 5, Immunization Schedules, Section 2.1, Minimum Intervals for Specific Vaccine Series for minimum interval scheduling. 2. Please note that websites are provided for non-publicly funded vaccines in Saskatchewan. All biological product monographs can be found in the Drug Product Database on the Health Canada website at: http://webprod3.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp. The Ministry of Health does not endorse products or manufacturer websites. 3. Post-exposure contact immunoprophylaxis management falls under the direction of a Medical Health Officer as per the Saskatchewan Communicable Disease Control Manual, available at: http://www.ehealthsask.ca/services/manuals/Pages/CDCManual.aspx . 1.0 ACTIVE IMMUNIZING AGENTS • Cholera – E. coli Vaccine (Chol-Ecol-O) o DUKORAL® • COVID – 19 o AstraZeneca/COVISHIELD o MODERNA o PFIZER • Third and Fourth COVID-19 Dose Recommendations for Travellers • Provision of COVID-19 Vaccine Booster Doses to Select Populations • Diphtheria-Tetanus-acellular Pertussis-Polio-Haemophilus influenzae type b Adsorbed Vaccine (DTaP- IPV-Hib) o INFANRIX™-IPV/Hib o PEDIACEL® • Diphtheria-Tetanus-acellular Pertussis-Hepatitis B-Polio-Haemophilus influenzae type b Adsorbed Vaccine (DTaP-HB-IPV-Hib) o INFANRIX™-hexa • Haemophilus influenzae type b Conjugate Vaccine (Hib) o Act-HIB ® o HIBERIX® • Hepatitis A Vaccine (HA) Indications • Hepatitis A Vaccine (HA) o Avaxim™ and Avaxim™ Pediatric o Havrix® 1440 and Havrix® 720 Junior o Vaqta® • Hepatitis A and B Vaccine Combined Vaccine (HAHB) o Twinrix™ and Twinrix Junior™ • Hepatitis A and Typhoid Vaccine (HA-Typh-I) o ViVAXIM® • Hepatitis B (HB) Vaccine Indications • Hepatitis B Vaccine - Immigrant Populations Ineligibility List • Hepatitis B Re-Vaccination Assessment Algorithm • Hepatitis B Series Completion Recommendations for Children 11-15 Years Old • Hepatitis B Vaccine Series Completion Scenarios • Hepatitis B Vaccine (HB) o ENGERIX®-B o RECOMBIVAX HB® • Herpes Zoster Vaccine o Shingrix™ (RZV) o ZOSTAVAX® II (LZV) Saskatchewan Immunization Manual Chapter 10 – Biological Products August 2021 • Human Papillomavirus Vaccine o CERVARIX™ (HPV-2) o GARDASIL®9 (HPV-9) • Influenza Vaccine o AFLURIA TETRA o FLUCELVAX® QUAD o FLULAVAL TETRA o FLUMIST QUADRIVALENT o FLUZONE® QUADRIVALENT o FLUZONE® HIGH DOSE QUADRIVALENT o INFLUVAC® TETRA • Japanese Encephalitis Vaccine (JE) o IXIARO™ • Measles-Mumps-Rubella Vaccine (MMR) o MMRII™ o PRIORIX™ • Measles-Mumps-Rubella-Varicella Vaccine (MMRV) o PRIORIX-Tetra™ o ProQuad™ • Meningococcal Conjugate C Vaccine (Men-C-C) o MENJUGATE™ Liquid o Neis Vac-C® • Meningococcal Conjugate ACYW-135 Vaccine (Men-C-ACYW-135) o Menactra® o Menveo™ o NIMENRIX™ • Multicomponent Meningococcal B Vaccine o BEXSERO® (MenB 4C) o Trumenba™ (MenB bivalent) • Pneumococcal Conjugate Vaccine o SYNFLORIX™ (Pneu-C-10) o Prevnar® 13 (Pneu-C-13) • Pneumococcal Polysaccharide Vaccine (Pneu-P-23) o PNEUMOVAX® 23 • Poliomyelitis Vaccine (Inactivated) (IPV) o IMOVAX® Polio • Rabies Vaccine (Rab) (Post-exposure prophylaxis) o IMOVAX® Rabies [Human Diploid Cell Vaccine (HDCV)] o RabAvert® [Purified Chick Embryo Cell Vaccine (PCECV)] • Rotavirus Vaccine o Rotarix™ (Rot-1) o RotaTeq® (Rot-5) Saskatchewan Immunization Manual Chapter 10 – Biological Products June 2020 • Tetanus-Diphtheria Adsorbed Vaccine (Td) o Td Adsorbed™ • Tetanus-Diphtheria-acellular Pertussis Vaccine (Tdap) o ADACEL® o BOOSTRIX™ • Tetanus-Diphtheria-acellular Pertussis-Inactivated Poliomyelitis Vaccine (Tdap-IPV) o ADACEL®-Polio o BOOSTRIX®-Polio™ • Typhoid Vaccine (Typh-I) (Salmonella Typhi Vi Capsular Polysaccharide) o Typhim Vi® • Typhoid Vaccine (Typh-O) (Live Oral Attenuated Ty 21a) o Vivotif® • Typhoid Vaccine (Typh-I) (Salmonella Typhi Vi Capsular Polysaccharide) o Typherix® • Varicella Vaccine (Var) o VARILRIX® o Varivax III™ • Yellow Fever Vaccine (YF) o YF-Vax™ 2.0 DIAGNOSTIC, PASSIVE IMMUNIZING AND ANTITOXIN AGENTS • Purified (tuberculosis) Protein Derivative (PPD) (Mantoux) o Tubersol® • Immune Globulin Preparation Injection Site, Needle Length and Total Site Volume per Age Group • Botulism Immune Globulin o BabyBIG • Hepatitis B Immune Globulin (HBIg) TM o HepaGam B o HyperHEP B™ S/D • Immune Globulin (Ig - Intramuscular) o GamaSTAN™ S/D • Rabies Immune Globulin (RabIg) o HYPERRAB™ S/D o IMOGAM® o KamRAB™ • Tetanus Immune Globulin (TIg) o HYPERTET™ S/D • Varicella Zoster Immune Globulin (VarIg) o VariZIG™ • Botulism Antitoxin (BAT) o Botulism Antitoxin • Diphtheria Antitoxin (DAT) o Diphtheria Antitoxin Saskatchewan Immunization Manual Chapter 10 – Biological Products April 2012 THIS CHAPTER MEETS THE FOLLOWING IMMUNIZATION COMPETENCIES FOR HEALTH PROFESSIONALS (PHAC, 2008): http://www.phac-aspc.gc.ca/im/pdf/ichp-cips-eng.pdf #4: The Types of Immunizing Agents and Their Composition ♦ Competency: Applies the knowledge of the components and properties of immunizing agents as needed for safe and effective practice. #8: Administration of Immunizing Agents ♦ Competency: Prepares and administers immunization agents correctly. #11: Populations Requiring Special Considerations ♦ Competency: Recognizes and responds to the unique immunization needs of certain population groups Saskatchewan Immunization Manual Chapter 10 – Biological Products August 2021 Cholera - E.coli (Chol-Ecol-O) [Non-publicly funded] DUKORAL® (Valneva Canada. 2020 product monograph available at: https://www.valneva.ca) Saskatchewan Immunization Manual Chapter 10 – Biological Products 2021-09-07 Page 1 of 5 COVID-19 Vaccine – AstraZeneca/COVISHIELD (Licensed for use in Canada February 26, 2021) Product monographs: AstraZeneca: https://covid-vaccine.canada.ca/info/pdf/astrazeneca-covid-19-vaccine-pm-en.pdf COVISHIELD: https://covid-vaccine.canada.ca/info/pdf/covishield-pm-en.pdf Recombinant Viral Vector Vaccine (Refrigerated Vaccine) Manufacturer AstraZeneca COVID-19 Vaccine: AstraZeneca COVISHIELD COVID-19 Vaccine: Serum Institute of India Licensed use Licensed for 18 years of age. Composition/Platform • Recombinant adenovirus vector encoding the viral spike glycoprotein Vaccine Type, Efficacy • Efficacy 62% after 2 doses in adults 18-64 years old • The interval between the first and second dose of the AstraZeneca/ COVISHIELD vaccine may impact efficacy of the vaccine, with lower efficacy if the interval is less than 12 weeks. • No adjuvants, preservatives, or antibiotics. Indications for use of • This vaccine is being offered in a phased approach. Please follow operational guidelines to provincially funded assess eligibility. vaccine Dose 0.5 mL Route • Intramuscular injection (IM) Schedule 2 doses • Dose 1: day 0 • Dose 2: minimum interval of 28 days (4 weeks). o NOTE: mRNA vaccine given at least 28 days later is preferred as the second dose for those who received AZ or COVISHIELD as their first dose, resulting in increased immunogenicity. • Refer to Third and Fourth COVID-19 Dose Recommendations for Travellers in this chapter. • As of September 7, 2021 the following people are eligible for an additional ‘booster dose’ • Transplant recipients (including solid organ, islet cell, tissue and hematopoietic stem cell transplants). • Recipients of stable, active treatment (chemotherapy, targeted therapies, immunotherapy) for malignant hematologic disorders • Recipients of an anti-CD20 agent (e.g. rituximab, ocrelizumab, ofatumumab). • Long-term care home and personal care home residents • For further details, refer to the Ministry of Health’s COVID – 19 Vaccine Contraindications and Precautions Background Document found in the COVID-19 Immunization Manual. Contraindications • Known severe hypersensitivity to any component of the vaccine. • One non-medicinal ingredient in the vaccine known to cause type 1 hypersensitivity reactions is polysorbate 80. The potential allergen may be found medical preparations (e.g., vitamin oils, tablets, and anticancer agents), cosmetics. • Anaphylaxis to previous dose of viral vector or mRNA COVID-19 vaccine. • History of capillary leak syndrome (CLS). • Thrombosis associated with lupus anticoagulant (thrombotic anti-phospholipid syndrome (APS)). • Major venous or arterial thrombosis with thrombocytopenia following a viral vector COVID-19 vaccine. • Individuals with a previous history of Heparin Induced Thrombocytopenia (HIT). (HIT antibody lingering might interfere with lab assay to detect VIPIT/VITT antibody and complicate management). • VITT: The reaction typically occurs 4 to 28 days, but may occur up to 42 days after Saskatchewan Immunization Manual Chapter 10 – Biological Products 2021-09-07 Page 2 of 5 vaccination. The number of people who are affected following immunization with this vaccine is about one out of every 26,000 to one out of every 100,000 persons after the first dose and about one out of every 600,000 persons after the second dose. The case fatality rate of VITT ranges between 20 and 50%. Precautions • Previous history of Cerebral Sinus Venous Thrombosis (CVST) with thrombocytopenia - should only receive a viral vector COVID-19 vaccine if the potential benefits outweigh the potential risks. An alternate COVID-19 vaccine should be offered. Thrombocytopenia and bleeding disorders • Individuals receiving anticoagulant therapy or those with a bleeding disorder that would contraindicate intramuscular injection should not be given the vaccine unless the potential benefit clearly outweighs the risk of administration. Concurrent Illness • Administration
Load more

Recommended publications
  • Healthcare Personnel Vaccination Recommendations1 Vaccine ­ Recommendations in Brief ­
    Healthcare Personnel Vaccination Recommendations1 Vaccine Recommendations in brief Hepatitis B Give 3-dose series (dose #1 now, #2 in 1 month, #3 approximately 5 months after #2). Give IM. Obtain anti-HBs serologic testing 1–2 months after dose #3. Influenza Give 1 dose of influenza vaccine annually. Give inactivated injectable influenza vaccine intramuscularly or live attenuated influenza vaccine (LAIV) intranasally. MMR For healthcare personnel (HCP) born in 1957 or later without serologic evidence of immunity or prior vaccination, give 2 doses of MMR, 4 weeks apart. For HCP born prior to 1957, see below. Give SC. Varicella For HCP who have no serologic proof of immunity, prior vaccination, or history of varicella disease, (chickenpox) give 2 doses of varicella vaccine, 4 weeks apart. Give SC. Tetanus, diphtheria, Give a one-time dose of Tdap as soon as feasible to all HCP who have not received Tdap previously. pertussis Give Td boosters every 10 years thereafter. Give IM. Meningococcal Give 1 dose to microbiologists who are routinely exposed to isolates of N. meningitidis. Give IM or SC. Hepatitis A, typhoid, and polio vaccines are not routinely recommended for HCP who may have on-the-job exposure to fecal material. Hepatitis B Healthcare personnel (HCP) who perform tasks that may involve exposure to of live rubella vaccine). HCP with 2 documented doses of MMR are not blood or body fluids should receive a 3-dose series of hepatitis B vaccine at recommended to be serologically tested for immunity; but if they are tested 0-, 1-, and 6-month intervals. Test for hepatitis B surface antibody (anti-HBs) and results are negative or equivocal for measles, mumps, and/or rubella, to document immunity 1–2 months after dose #3.
    [Show full text]
  • (ACIP) General Best Guidance for Immunization
    9. Special Situations Updates Major revisions to this section of the best practices guidance include the timing of intramuscular administration and the timing of clotting factor deficiency replacement. Concurrent Administration of Antimicrobial Agents and Vaccines With a few exceptions, use of an antimicrobial agent does not interfere with the effectiveness of vaccination. Antibacterial agents have no effect on inactivated, recombinant subunit, or polysaccharide vaccines or toxoids. They also have no effect on response to live, attenuated vaccines, except BCG vaccines. Antimicrobial or immunosuppressive agents may interfere with the immune response to BCG and should only be used under medical supervision (for additional information, see www.merck.com/product/usa/pi_circulars/b/bcg/bcg_pi.pdf). Antiviral drugs used for treatment or prophylaxis of influenza virus infections have no effect on the response to inactivated influenza vaccine (2). However, live, attenuated influenza vaccine should not be administered until 48 hours after cessation of therapy with antiviral influenza drugs. If feasible, to avoid possible reduction in vaccine effectiveness, antiviral medication should not be administered for 14 days after LAIV administration (2). If influenza antiviral medications are administered within 2 weeks after receipt of LAIV, the LAIV dose should be repeated 48 or more hours after the last dose of zanamavir or oseltamivir. The LAIV dose should be repeated 5 days after peramivir and 17 days after baloxavir. Alternatively, persons receiving antiviral drugs within the period 2 days before to 14 days after vaccination with LAIV may be revaccinated with another approved vaccine formulation (e.g., IIV or recombinant influenza vaccine). Antiviral drugs active against herpesviruses (e.g., acyclovir or valacyclovir) might reduce the efficacy of vaccines containing live, attenuated varicella zoster virus (i.e., Varivax and ProQuad) (3,4).
    [Show full text]
  • Adjuvants and Additives in Human and Animal Vaccines
    Medical Research Archives Volume 2 Issue 5 July 2016. Adjuvants and Additives in Human and Animal Vaccines ADJUVANTS AND ADDITIVES IN HUMAN AND ANIMAL VACCINES *Author W. Jean Dodds, DVM Hemopet, 938 Stanford Street, Santa Monica, California, United States of America Email: [email protected] Abstract : Vaccines typically contain immunologic adjuvants and other additives which act to accelerate, prolong, or enhance antigen-specific immune responses when used together with specific vaccine antigens. Nevertheless, despite ongoing questions about their efficacy and safety, millions of individuals have received these vaccines with relatively few documented adverse events. Vaccine pharmacovigilance is the term used to remind all of us that vaccines carry an inherent, albeit small, risk ( CIOMS/WHO 2012) . Key words: vaccine, adjuvants, additives Copyright 2016 KEI Journals. All rights reserved. 1 Medical Research Archives Volume 2 Issue 5 July 2016. Adjuvants and Additives in Human and Animal Vaccines Introduction: Tomljenovic L 2013, Shaw CA, Li D and Countless individuals have been vaccinated Tomljenovic L 2014, Spickler AR and Roth routinely and repeatedly for the common, JA 2003, Stejskal V 2013, Tomljenovic L and Shaw CA 2012, 2016, Vogel FR 2000, serious infectious viral and bacterial diseases without obvious untoward effects Wilson-Welder JH et al. 2009). (Dodds WJ 1997, 1999, Tizard I 1990, While current vaccine adjuvants can Wellborn LV et al. 2011). But, medical successfully generate humoral antibody- professionals still need to be aware of the mediated protection, other diseases such as potential for adverse events (AE) and tuberculosis and malaria require a cell- determine what constitutes "acceptable" mediated immune response for adequate harm (Dodds WJ 1997,1999, Tizard I 1990).
    [Show full text]
  • Safety of Immunization During Pregnancy a Review of the Evidence
    Safety of Immunization during Pregnancy A review of the evidence Global Advisory Committee on Vaccine Safety © World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied.
    [Show full text]
  • Mmrv Vaccine
    VACCINE INFORMATION STATEMENT (Measles, Mumps, Many Vaccine Information Statements are available in Spanish and other languages. MMRV Vaccine Rubella and See www.immunize.org/vis Varicella) Hojas de información sobre vacunas están disponibles en español y en muchos otros What You Need to Know idiomas. Visite www.immunize.org/vis These are recommended ages. But children can get the Measles, Mumps, Rubella and second dose up through 12 years as long as it is at least 1 Varicella 3 months after the first dose. Measles, Mumps, Rubella, and Varicella (chickenpox) can be serious diseases: Children may also get these vaccines as 2 separate shots: MMR (measles, mumps and rubella) and Measles varicella vaccines. • Causes rash, cough, runny nose, eye irritation, fever. • Can lead to ear infection, pneumonia, seizures, brain 1 Shot (MMRV) or 2 Shots (MMR & Varicella)? damage, and death. • Both options give the same protection. Mumps • One less shot with MMRV. • Causes fever, headache, swollen glands. • Children who got the first dose as MMRV have • Can lead to deafness, meningitis (infection of the brain had more fevers and fever-related seizures (about and spinal cord covering), infection of the pancreas, 1 in 1,250) than children who got the first dose as painful swelling of the testicles or ovaries, and, rarely, separate shots of MMR and varicella vaccines on death. the same day (about 1 in 2,500). Rubella (German Measles) Your doctor can give you more information, • Causes rash and mild fever; and can cause arthritis, including the Vaccine Information Statements for (mostly in women). MMR and Varicella vaccines.
    [Show full text]
  • 1 Complaint 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
    Case 1:20-cv-00364 Document 1 Filed 08/19/20 Page 1 of 82 PageID #: 1 1 IN THE UNITED STATES DISTRICT COURT 2 FOR THE DISTRICT OF RHODE ISLAND 3 JULIA BALASCO, Case No. 4 Plaintiff, 5 v. COMPLAINT FOR 6 MERCK & CO., INC., a New Jersey Corporation; (1) Negligence and MERCK SHARP & DOHME CORP., a New (2) Strict Liability (Failure to Warn) 7 Jersey Corporation, (3) Strict Liability (Manufacturing Defect) 8 Defendants. (4) Breach of Warranty 9 (5) Common Law Fraud 10 (6) Violation of Rhode Island’s Deceptive Trade Practices Act 11 12 DEMAND FOR JURY TRIAL 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 1 COMPLAINT Case 1:20-cv-00364 Document 1 Filed 08/19/20 Page 2 of 82 PageID #: 2 TABLE OF CONTENTS 1 2 INTRODUCTION ................................................................................................................................... 5 3 PARTIES AND VENUE ........................................................................................................................ 5 4 GENERAL ALLEGATIONS ................................................................................................................. 7 5 I. “History Doesn’t Repeat Itself, But It Often Rhymes” – Mark Twain ........................................ 7 6 II. In Bringing Its Holy Grail, Gardasil, to Market, Merck Engaged in the Same Fraudulent 7 Research and Marketing It Had Engaged in Vis-à-vis Vioxx Resulting In Patients Being 8 Exposed to a Vaccine That is Of Questionable Efficacy and Which Can Cause Serious and Debilitating Adverse Events ........................................................................................................
    [Show full text]
  • The Hepatitis B Vaccine Is the Most Widely Used Vaccine in the World, with Over 1 Billion Doses Given
    Hepatitis B Vaccine Protect Yourself and Those You Love What is Hepatitis B? Hepatitis B is the most common serious liver infection in the world. It is caused by the hepatitis B virus (HBV), which attacks liver cells and can lead to liver failure, cirrhosis (scarring), or liver cancer later in life. The virus is transmitted through direct contact with infected blood and bodily fluids, and from an infected woman to her newborn at birth. Is there a safe vaccine for hepatitis B? YES! The good news is that there is a safe and effective vaccine for hepatitis B. The vaccine is a series, typically given as three shots over a six-month period that will provide a lifetime of protection. You cannot get hepatitis B from the vaccine – there is no human blood or live virus in the vaccine. The hepatitis B vaccine is the most widely used vaccine in the world, with over 1 billion doses given. The hepatitis B vaccine is the first "anti-cancer" vaccine because it can help prevent liver cancer! Who should be vaccinated against hepatitis B? The World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) recommend the hepatitis B vaccine for all newborns and children up to 18 years of age, and all high-risk adults. All infants should receive the first dose of the vaccine in the delivery room or in the first 24 hours of life, preferably within 12 hours. (CDC recommends the first dose within 12 hours vs. the WHO recommendation of 24 hours.) The HBV vaccine is recommended to anyone who is at high risk of infection.
    [Show full text]
  • (ACIP) General Best Guidance for Immunization
    8. Altered Immunocompetence Updates This section incorporates general content from the Infectious Diseases Society of America policy statement, 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host (1), to which CDC provided input in November 2011. The evidence supporting this guidance is based on expert opinion and arrived at by consensus. General Principles Altered immunocompetence, a term often used synonymously with immunosuppression, immunodeficiency, and immunocompromise, can be classified as primary or secondary. Primary immunodeficiencies generally are inherited and include conditions defined by an inherent absence or quantitative deficiency of cellular, humoral, or both components that provide immunity. Examples include congenital immunodeficiency diseases such as X- linked agammaglobulinemia, SCID, and chronic granulomatous disease. Secondary immunodeficiency is acquired and is defined by loss or qualitative deficiency in cellular or humoral immune components that occurs as a result of a disease process or its therapy. Examples of secondary immunodeficiency include HIV infection, hematopoietic malignancies, treatment with radiation, and treatment with immunosuppressive drugs. The degree to which immunosuppressive drugs cause clinically significant immunodeficiency generally is dose related and varies by drug. Primary and secondary immunodeficiencies might include a combination of deficits in both cellular and humoral immunity. Certain conditions like asplenia and chronic renal disease also can cause altered immunocompetence. Determination of altered immunocompetence is important to the vaccine provider because incidence or severity of some vaccine-preventable diseases is higher in persons with altered immunocompetence; therefore, certain vaccines (e.g., inactivated influenza vaccine, pneumococcal vaccines) are recommended specifically for persons with these diseases (2,3). Administration of live vaccines might need to be deferred until immune function has improved.
    [Show full text]
  • Adult Vaccines
    What do flu, whooping cough, measles, shingles and pneumonia have in common? 1 They’re viruses that can make you very sick. 2 Vaccines can help prevent them. Protect yourself and those you care about. Get vaccinated at a network pharmacy near you. • Ask your pharmacist which vaccines are right for you. • Find out if your pharmacist can administer the recommended vaccinations. • Many vaccinations are covered by your plan at participating retail pharmacies. • Don’t forget to present your member ID card to the pharmacist at the time of service! The following vaccines are available and can be administered by pharmacists at participating network pharmacies: • Flu (seasonal influenza) • Meningitis • Travel Vaccines (typhoid, yellow • Tetanus/Diphtheria/Pertussis • Pneumonia fever, etc.) • Hepatitis • Rabies • Childhood Vaccines (MMR, etc.) • Human Papillomavirus (HPV) • Shingles/Zoster See other side for recommended adult vaccinations. The vaccinations you need ALL adults should get vaccinated for1: • Flu, every year. It’s especially important for pregnant women, older adults and people with chronic health conditions. • Tetanus, diphtheria and pertussis (whooping cough). Adults should get a one-time dose of the Tdap vaccine. It’s different from the tetanus vaccine (Td), which is given every 10 years. You may need additional vaccinations depending on your age1: Young adults not yet vaccinated need: Human papillomavirus (HPV) vaccine series (3 doses) if you are: • Female age 26 or younger • Male age 21 or younger • Male age 26 or younger who has sex with men, who is immunocompromised or who has HIV Adults born in the U.S. in 1957 or after need: Measles, mumps, rubella (MMR) vaccine2 Adults should get at least one dose of MMR vaccine, unless they’ve already gotten this vaccine or have immunity to measles, mumps and rubella Adults born in the U.S.
    [Show full text]
  • Engerix-B Data Sheet
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME ENGERIX-B 20 micrograms/mL, suspension for injection. ENGERIX-B paediatric 10 micrograms/0.5 mL, suspension for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ENGERIX-B paediatric dose: 10 microgram (µg) dose vaccine 1 dose (0.5 mL) contains: Hepatitis B surface antigen 1, 2 10 micrograms 1Adsorbed on aluminium hydroxide, hydrated Total: 0.25 milligrams Al3+ 2Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology ENGERIX-B: 20 microgram (µg) dose vaccine 1 dose (1 mL) contains: Hepatitis B surface antigen1, 2 20 micrograms 1Adsorbed on aluminium hydroxide, hydrated Total: 0.50 milligrams Al3+ 2Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology The vaccine is highly purified, and meets the WHO requirements for recombinant hepatitis B vaccines. No substances of human origin are used in its manufacture. For the full list of excipients, see section 6.1 List of excipients. 3. PHARMACEUTICAL FORM Suspension for injection. ENGERIX-B is a turbid white suspension. Upon storage, a fine white deposit with a clear colourless supernatant may be observed. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications ENGERIX-B is indicated for active immunisation against hepatitis B virus infection. As part of the national immunisation schedule, the New Zealand Ministry of Health* recommend all infants, unvaccinated children up to the age of 16 years, and household and sexual contacts of known hepatitis B carriers receive a primary course of vaccination against hepatitis B. 1 Immunisation is also recommended for seronegative persons who are at substantial risk and have been demonstrated or judged to be susceptible to the hepatitis B virus (HBV).
    [Show full text]
  • Vaccine Information for PARENTS and CAREGIVERS
    NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES Division of the National Health Laboratory Service VACCINE INFOR MATION FOR PARENTS & CAREGIVERS First Edition November 2016 Editors-in-Chief Nkengafac Villyen Motaze (MD, MSc, PhD fellow), Melinda Suchard (MBBCh, FCPath (SA), MMed) Edited by: Cheryl Cohen, (MBBCh, FCPath (SA) Micro, DTM&H, MSc (Epi), Phd) Lee Baker, (Dip Pharm) Lucille Blumberg, (MBBCh, MMed (Micro) ID (SA) FFTM (RCPS, Glasgow) DTM&H DOH DCH) Published by: Ideas Wise and Wonderful (IWW) for National Institute for Communicable Diseases (NICD) First Edition: Copyright © 2016 Contributions by: Clement Adu-Gyamfi (BSc Hons, MSc), Jayendrie Thaver (BSc), Kerrigan McCarthy, (MBBCh, FCPath (SA), DTM&H, MPhil (Theol) Kirsten Redman (BSc Hons), Nishi Prabdial-Sing (PhD), Nonhlanhla Mbenenge (MBBCh, MMED) Philippa Hime (midwife), Vania Duxbury (BSc Hons), Wayne Howard (BSc Hons) Acknowledgments: Amayeza, Vaccine Information Centre (http://www.amayeza-info.co.za/) Centre for Communicable Diseases Fact Sheets (http://www.cdc.gov/vaccines/hcp/vis/) World Health Organization Fact Sheets (http://www.who.int/mediacentre/factsheets/en/) National Department of Health, South Africa (http://www.health.gov.za/) Disclaimer This book is intended as an educational tool only. Information may be subject to change as schedules or formulations are updated. Summarized and simplified information is presented in this booklet. For full prescribing information and contraindications for vaccinations, please consult individual package inserts. There has been
    [Show full text]
  • Systematic Scoping Review on Social Media Monitoring Methods and Interventions Relating to Vaccine Hesitancy
    TECHNICAL REPORT Systematic scoping review on social media monitoring methods and interventions relating to vaccine hesitancy www.ecdc.europa.eu ECDC TECHNICAL REPORT Systematic scoping review on social media monitoring methods and interventions relating to vaccine hesitancy This report was commissioned by the European Centre for Disease Prevention and Control (ECDC) and coordinated by Kate Olsson with the support of Judit Takács. The scoping review was performed by researchers from the Vaccine Confidence Project, at the London School of Hygiene & Tropical Medicine (contract number ECD8894). Authors: Emilie Karafillakis, Clarissa Simas, Sam Martin, Sara Dada, Heidi Larson. Acknowledgements ECDC would like to acknowledge contributions to the project from the expert reviewers: Dan Arthus, University College London; Maged N Kamel Boulos, University of the Highlands and Islands, Sandra Alexiu, GP Association Bucharest and Franklin Apfel and Sabrina Cecconi, World Health Communication Associates. ECDC would also like to acknowledge ECDC colleagues who reviewed and contributed to the document: John Kinsman, Andrea Würz and Marybelle Stryk. Suggested citation: European Centre for Disease Prevention and Control. Systematic scoping review on social media monitoring methods and interventions relating to vaccine hesitancy. Stockholm: ECDC; 2020. Stockholm, February 2020 ISBN 978-92-9498-452-4 doi: 10.2900/260624 Catalogue number TQ-04-20-076-EN-N © European Centre for Disease Prevention and Control, 2020 Reproduction is authorised, provided the
    [Show full text]